nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SRC—type 2 diabetes mellitus	0.212	0.619	CbGaD
Dasatinib—CYP1A2—type 2 diabetes mellitus	0.0788	0.229	CbGaD
Dasatinib—CYP3A4—type 2 diabetes mellitus	0.0522	0.152	CbGaD
Dasatinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0176	0.0852	CbGbCtD
Dasatinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0161	0.0779	CbGbCtD
Dasatinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0157	0.0759	CbGbCtD
Dasatinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0132	0.0639	CbGbCtD
Dasatinib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.012	0.0579	CbGbCtD
Dasatinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0113	0.0549	CbGbCtD
Dasatinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0106	0.051	CbGbCtD
Dasatinib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00943	0.0456	CbGbCtD
Dasatinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0094	0.0455	CbGbCtD
Dasatinib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00892	0.0431	CbGbCtD
Dasatinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0086	0.0416	CbGbCtD
Dasatinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00816	0.0395	CbGbCtD
Dasatinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0078	0.0377	CbGbCtD
Dasatinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00752	0.0364	CbGbCtD
Dasatinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0068	0.0329	CbGbCtD
Dasatinib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00608	0.0294	CbGbCtD
Dasatinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00581	0.0281	CbGbCtD
Dasatinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00531	0.0257	CbGbCtD
Dasatinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00515	0.0249	CbGbCtD
Dasatinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00494	0.0239	CbGbCtD
Dasatinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00494	0.0239	CbGbCtD
Dasatinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00467	0.0226	CbGbCtD
Dasatinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00348	0.0168	CbGbCtD
Dasatinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00318	0.0154	CbGbCtD
Dasatinib—BMPR1B—peripheral nervous system—type 2 diabetes mellitus	0.00206	0.023	CbGeAlD
Dasatinib—PDGFRA—penis—type 2 diabetes mellitus	0.00201	0.0224	CbGeAlD
Dasatinib—ERBB3—peripheral nervous system—type 2 diabetes mellitus	0.00155	0.0173	CbGeAlD
Dasatinib—EPHB3—nerve—type 2 diabetes mellitus	0.00146	0.0163	CbGeAlD
Dasatinib—MAP3K3—peripheral nervous system—type 2 diabetes mellitus	0.00131	0.0146	CbGeAlD
Dasatinib—EPHA4—nerve—type 2 diabetes mellitus	0.00122	0.0136	CbGeAlD
Dasatinib—EPHB1—retina—type 2 diabetes mellitus	0.00112	0.0124	CbGeAlD
Dasatinib—RIPK2—endothelium—type 2 diabetes mellitus	0.00107	0.012	CbGeAlD
Dasatinib—TESK1—Enalapril—Nateglinide—type 2 diabetes mellitus	0.00103	0.394	CbGdCrCtD
Dasatinib—STAT5B—islet of Langerhans—type 2 diabetes mellitus	0.000972	0.0108	CbGeAlD
Dasatinib—EPHB1—kidney—type 2 diabetes mellitus	0.000923	0.0103	CbGeAlD
Dasatinib—EPHB2—retina—type 2 diabetes mellitus	0.000916	0.0102	CbGeAlD
Dasatinib—SRC—artery—type 2 diabetes mellitus	0.000913	0.0102	CbGeAlD
Dasatinib—EPHB4—endothelium—type 2 diabetes mellitus	0.000907	0.0101	CbGeAlD
Dasatinib—EPHB1—adipose tissue—type 2 diabetes mellitus	0.000832	0.00929	CbGeAlD
Dasatinib—BMX—cardiovascular system—type 2 diabetes mellitus	0.000793	0.00885	CbGeAlD
Dasatinib—SRC—endothelium—type 2 diabetes mellitus	0.000771	0.0086	CbGeAlD
Dasatinib—EPHA3—retina—type 2 diabetes mellitus	0.000768	0.00857	CbGeAlD
Dasatinib—TEC—liver—type 2 diabetes mellitus	0.000744	0.0083	CbGeAlD
Dasatinib—SRMS—kidney—type 2 diabetes mellitus	0.000742	0.00828	CbGeAlD
Dasatinib—SIK2—adipose tissue—type 2 diabetes mellitus	0.000735	0.0082	CbGeAlD
Dasatinib—TESK1—islet of Langerhans—type 2 diabetes mellitus	0.000718	0.00801	CbGeAlD
Dasatinib—SIK3—nephron tubule—type 2 diabetes mellitus	0.000703	0.00785	CbGeAlD
Dasatinib—STAT5B—cardiovascular system—type 2 diabetes mellitus	0.000703	0.00784	CbGeAlD
Dasatinib—BMX—adipose tissue—type 2 diabetes mellitus	0.000699	0.0078	CbGeAlD
Dasatinib—STAT5B—kidney—type 2 diabetes mellitus	0.000687	0.00767	CbGeAlD
Dasatinib—STAT5B—pancreas—type 2 diabetes mellitus	0.000683	0.00762	CbGeAlD
Dasatinib—EPHA5—retina—type 2 diabetes mellitus	0.00068	0.00758	CbGeAlD
Dasatinib—STK35—islet of Langerhans—type 2 diabetes mellitus	0.000662	0.00739	CbGeAlD
Dasatinib—CSK—islet of Langerhans—type 2 diabetes mellitus	0.000658	0.00734	CbGeAlD
Dasatinib—KIT—endothelium—type 2 diabetes mellitus	0.000628	0.00701	CbGeAlD
Dasatinib—TESK1—Enalapril—Ramipril—type 2 diabetes mellitus	0.000626	0.24	CbGdCrCtD
Dasatinib—STAT5B—adipose tissue—type 2 diabetes mellitus	0.00062	0.00691	CbGeAlD
Dasatinib—RIPK2—islet of Langerhans—type 2 diabetes mellitus	0.00061	0.00681	CbGeAlD
Dasatinib—SIK3—cortex of kidney—type 2 diabetes mellitus	0.000602	0.00672	CbGeAlD
Dasatinib—SIK1—islet of Langerhans—type 2 diabetes mellitus	0.000596	0.00665	CbGeAlD
Dasatinib—ZAK—cardiovascular system—type 2 diabetes mellitus	0.000587	0.00655	CbGeAlD
Dasatinib—EPHB1—liver—type 2 diabetes mellitus	0.000584	0.00651	CbGeAlD
Dasatinib—TESK1—nephron tubule—type 2 diabetes mellitus	0.000578	0.00645	CbGeAlD
Dasatinib—EPHA3—adipose tissue—type 2 diabetes mellitus	0.000573	0.00639	CbGeAlD
Dasatinib—SIK3—adipose tissue—type 2 diabetes mellitus	0.000557	0.00622	CbGeAlD
Dasatinib—CSK—nephron tubule—type 2 diabetes mellitus	0.00053	0.00591	CbGeAlD
Dasatinib—RIPK2—retina—type 2 diabetes mellitus	0.000522	0.00582	CbGeAlD
Dasatinib—ZAK—adipose tissue—type 2 diabetes mellitus	0.000518	0.00578	CbGeAlD
Dasatinib—EPHB4—islet of Langerhans—type 2 diabetes mellitus	0.000516	0.00575	CbGeAlD
Dasatinib—SIK2—liver—type 2 diabetes mellitus	0.000516	0.00575	CbGeAlD
Dasatinib—EPHA2—islet of Langerhans—type 2 diabetes mellitus	0.000506	0.00565	CbGeAlD
Dasatinib—FRK—liver—type 2 diabetes mellitus	0.000502	0.00561	CbGeAlD
Dasatinib—BMPR1B—adipose tissue—type 2 diabetes mellitus	0.000497	0.00554	CbGeAlD
Dasatinib—ERBB3—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000497	0.19	CbGdCrCtD
Dasatinib—TESK1—cortex of kidney—type 2 diabetes mellitus	0.000495	0.00552	CbGeAlD
Dasatinib—BTK—adipose tissue—type 2 diabetes mellitus	0.000494	0.00551	CbGeAlD
Dasatinib—MAP4K5—islet of Langerhans—type 2 diabetes mellitus	0.000494	0.00551	CbGeAlD
Dasatinib—RIPK2—nephron tubule—type 2 diabetes mellitus	0.000492	0.00548	CbGeAlD
Dasatinib—TNK2—adipose tissue—type 2 diabetes mellitus	0.000487	0.00543	CbGeAlD
Dasatinib—STK36—cortex of kidney—type 2 diabetes mellitus	0.000487	0.00543	CbGeAlD
Dasatinib—SIK1—nephron tubule—type 2 diabetes mellitus	0.00048	0.00536	CbGeAlD
Dasatinib—CSK—cardiovascular system—type 2 diabetes mellitus	0.000476	0.00531	CbGeAlD
Dasatinib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000472	0.00526	CbGeAlD
Dasatinib—LIMK2—cortex of kidney—type 2 diabetes mellitus	0.000471	0.00525	CbGeAlD
Dasatinib—ERBB3—nephron tubule—type 2 diabetes mellitus	0.00047	0.00525	CbGeAlD
Dasatinib—MAP3K2—nephron tubule—type 2 diabetes mellitus	0.000466	0.0052	CbGeAlD
Dasatinib—CSK—kidney—type 2 diabetes mellitus	0.000465	0.00519	CbGeAlD
Dasatinib—STK35—pancreas—type 2 diabetes mellitus	0.000465	0.00519	CbGeAlD
Dasatinib—CSK—pancreas—type 2 diabetes mellitus	0.000462	0.00516	CbGeAlD
Dasatinib—CSK—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000458	0.176	CbGdCrCtD
Dasatinib—TESK1—adipose tissue—type 2 diabetes mellitus	0.000458	0.00511	CbGeAlD
Dasatinib—YES1—islet of Langerhans—type 2 diabetes mellitus	0.000456	0.00509	CbGeAlD
Dasatinib—CSK—cortex of kidney—type 2 diabetes mellitus	0.000453	0.00506	CbGeAlD
Dasatinib—STK36—adipose tissue—type 2 diabetes mellitus	0.000451	0.00503	CbGeAlD
Dasatinib—RIPK2—cardiovascular system—type 2 diabetes mellitus	0.000441	0.00493	CbGeAlD
Dasatinib—SRC—islet of Langerhans—type 2 diabetes mellitus	0.000439	0.00489	CbGeAlD
Dasatinib—LIMK2—adipose tissue—type 2 diabetes mellitus	0.000436	0.00486	CbGeAlD
Dasatinib—STAT5B—liver—type 2 diabetes mellitus	0.000435	0.00485	CbGeAlD
Dasatinib—STK35—adipose tissue—type 2 diabetes mellitus	0.000422	0.00471	CbGeAlD
Dasatinib—SIK1—kidney—type 2 diabetes mellitus	0.000422	0.00471	CbGeAlD
Dasatinib—CSK—adipose tissue—type 2 diabetes mellitus	0.000419	0.00468	CbGeAlD
Dasatinib—SIK1—pancreas—type 2 diabetes mellitus	0.000419	0.00468	CbGeAlD
Dasatinib—EPHB4—nephron tubule—type 2 diabetes mellitus	0.000415	0.00463	CbGeAlD
Dasatinib—HCK—adipose tissue—type 2 diabetes mellitus	0.000414	0.00462	CbGeAlD
Dasatinib—ERBB3—kidney—type 2 diabetes mellitus	0.000413	0.00461	CbGeAlD
Dasatinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000411	0.00459	CbGeAlD
Dasatinib—SIK1—cortex of kidney—type 2 diabetes mellitus	0.000411	0.00458	CbGeAlD
Dasatinib—ERBB3—pancreas—type 2 diabetes mellitus	0.000411	0.00458	CbGeAlD
Dasatinib—EPHA2—nephron tubule—type 2 diabetes mellitus	0.000407	0.00455	CbGeAlD
Dasatinib—FYN—nephron tubule—type 2 diabetes mellitus	0.000407	0.00454	CbGeAlD
Dasatinib—MAP3K3—nephron tubule—type 2 diabetes mellitus	0.000397	0.00443	CbGeAlD
Dasatinib—MAPK14—cardiovascular system—type 2 diabetes mellitus	0.000393	0.00439	CbGeAlD
Dasatinib—FGR—cardiovascular system—type 2 diabetes mellitus	0.000392	0.00437	CbGeAlD
Dasatinib—SIK3—liver—type 2 diabetes mellitus	0.000391	0.00436	CbGeAlD
Dasatinib—YES1—retina—type 2 diabetes mellitus	0.00039	0.00435	CbGeAlD
Dasatinib—RIPK2—adipose tissue—type 2 diabetes mellitus	0.000389	0.00434	CbGeAlD
Dasatinib—MAPK14—kidney—type 2 diabetes mellitus	0.000385	0.0043	CbGeAlD
Dasatinib—SIK1—adipose tissue—type 2 diabetes mellitus	0.00038	0.00424	CbGeAlD
Dasatinib—EPHA4—adipose tissue—type 2 diabetes mellitus	0.000376	0.0042	CbGeAlD
Dasatinib—SRC—retina—type 2 diabetes mellitus	0.000375	0.00418	CbGeAlD
Dasatinib—EPHB4—cardiovascular system—type 2 diabetes mellitus	0.000373	0.00416	CbGeAlD
Dasatinib—ERBB3—adipose tissue—type 2 diabetes mellitus	0.000373	0.00416	CbGeAlD
Dasatinib—JAK2—cardiovascular system—type 2 diabetes mellitus	0.00037	0.00413	CbGeAlD
Dasatinib—MAP3K2—adipose tissue—type 2 diabetes mellitus	0.000369	0.00412	CbGeAlD
Dasatinib—YES1—nephron tubule—type 2 diabetes mellitus	0.000367	0.0041	CbGeAlD
Dasatinib—EPHA2—cardiovascular system—type 2 diabetes mellitus	0.000366	0.00408	CbGeAlD
Dasatinib—FYN—cardiovascular system—type 2 diabetes mellitus	0.000365	0.00408	CbGeAlD
Dasatinib—EPHB4—kidney—type 2 diabetes mellitus	0.000365	0.00407	CbGeAlD
Dasatinib—ZAK—liver—type 2 diabetes mellitus	0.000363	0.00405	CbGeAlD
Dasatinib—EPHB4—pancreas—type 2 diabetes mellitus	0.000363	0.00405	CbGeAlD
Dasatinib—JAK2—kidney—type 2 diabetes mellitus	0.000362	0.00404	CbGeAlD
Dasatinib—FYN—kidney—type 2 diabetes mellitus	0.000357	0.00399	CbGeAlD
Dasatinib—MAP3K3—cardiovascular system—type 2 diabetes mellitus	0.000357	0.00398	CbGeAlD
Dasatinib—EPHA2—pancreas—type 2 diabetes mellitus	0.000356	0.00397	CbGeAlD
Dasatinib—EPHB4—cortex of kidney—type 2 diabetes mellitus	0.000355	0.00397	CbGeAlD
Dasatinib—LYN—liver—type 2 diabetes mellitus	0.000354	0.00395	CbGeAlD
Dasatinib—JAK2—cortex of kidney—type 2 diabetes mellitus	0.000353	0.00394	CbGeAlD
Dasatinib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000349	0.0039	CbGeAlD
Dasatinib—FYN—cortex of kidney—type 2 diabetes mellitus	0.000348	0.00388	CbGeAlD
Dasatinib—MAPK14—adipose tissue—type 2 diabetes mellitus	0.000347	0.00387	CbGeAlD
Dasatinib—MAP4K5—pancreas—type 2 diabetes mellitus	0.000347	0.00387	CbGeAlD
Dasatinib—BTK—liver—type 2 diabetes mellitus	0.000347	0.00387	CbGeAlD
Dasatinib—FGR—adipose tissue—type 2 diabetes mellitus	0.000346	0.00386	CbGeAlD
Dasatinib—LCK—adipose tissue—type 2 diabetes mellitus	0.000346	0.00386	CbGeAlD
Dasatinib—TNK2—liver—type 2 diabetes mellitus	0.000342	0.00381	CbGeAlD
Dasatinib—MAP4K5—cortex of kidney—type 2 diabetes mellitus	0.00034	0.0038	CbGeAlD
Dasatinib—MAP3K3—cortex of kidney—type 2 diabetes mellitus	0.00034	0.0038	CbGeAlD
Dasatinib—FMO3—adipose tissue—type 2 diabetes mellitus	0.000334	0.00372	CbGeAlD
Dasatinib—EPHB4—adipose tissue—type 2 diabetes mellitus	0.000329	0.00367	CbGeAlD
Dasatinib—JAK2—adipose tissue—type 2 diabetes mellitus	0.000327	0.00364	CbGeAlD
Dasatinib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.000325	0.00363	CbGeAlD
Dasatinib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000323	0.00361	CbGeAlD
Dasatinib—EPHA2—adipose tissue—type 2 diabetes mellitus	0.000323	0.0036	CbGeAlD
Dasatinib—YES1—kidney—type 2 diabetes mellitus	0.000323	0.0036	CbGeAlD
Dasatinib—FYN—adipose tissue—type 2 diabetes mellitus	0.000322	0.00359	CbGeAlD
Dasatinib—TESK1—liver—type 2 diabetes mellitus	0.000321	0.00358	CbGeAlD
Dasatinib—YES1—pancreas—type 2 diabetes mellitus	0.00032	0.00358	CbGeAlD
Dasatinib—SRC—cardiovascular system—type 2 diabetes mellitus	0.000317	0.00354	CbGeAlD
Dasatinib—STK36—liver—type 2 diabetes mellitus	0.000316	0.00353	CbGeAlD
Dasatinib—MAP3K3—adipose tissue—type 2 diabetes mellitus	0.000315	0.00351	CbGeAlD
Dasatinib—MAP4K5—adipose tissue—type 2 diabetes mellitus	0.000315	0.00351	CbGeAlD
Dasatinib—YES1—cortex of kidney—type 2 diabetes mellitus	0.000314	0.00351	CbGeAlD
Dasatinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000311	0.00347	CbGeAlD
Dasatinib—SRC—kidney—type 2 diabetes mellitus	0.00031	0.00346	CbGeAlD
Dasatinib—SRC—pancreas—type 2 diabetes mellitus	0.000308	0.00344	CbGeAlD
Dasatinib—LIMK2—liver—type 2 diabetes mellitus	0.000305	0.00341	CbGeAlD
Dasatinib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.000301	0.00336	CbGeAlD
Dasatinib—STK35—liver—type 2 diabetes mellitus	0.000296	0.0033	CbGeAlD
Dasatinib—CSK—liver—type 2 diabetes mellitus	0.000294	0.00328	CbGeAlD
Dasatinib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000292	0.00326	CbGeAlD
Dasatinib—YES1—adipose tissue—type 2 diabetes mellitus	0.000291	0.00324	CbGeAlD
Dasatinib—HCK—liver—type 2 diabetes mellitus	0.00029	0.00324	CbGeAlD
Dasatinib—ABL2—liver—type 2 diabetes mellitus	0.000289	0.00322	CbGeAlD
Dasatinib—KIT—nephron tubule—type 2 diabetes mellitus	0.000288	0.00321	CbGeAlD
Dasatinib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000285	0.00318	CbGeAlD
Dasatinib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000285	0.00318	CbGeAlD
Dasatinib—SRC—adipose tissue—type 2 diabetes mellitus	0.00028	0.00312	CbGeAlD
Dasatinib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000278	0.0031	CbGeAlD
Dasatinib—RIPK2—liver—type 2 diabetes mellitus	0.000273	0.00305	CbGeAlD
Dasatinib—SIK1—liver—type 2 diabetes mellitus	0.000267	0.00297	CbGeAlD
Dasatinib—ABL1—retina—type 2 diabetes mellitus	0.000266	0.00297	CbGeAlD
Dasatinib—ERBB3—liver—type 2 diabetes mellitus	0.000261	0.00292	CbGeAlD
Dasatinib—MAP3K2—liver—type 2 diabetes mellitus	0.000259	0.00289	CbGeAlD
Dasatinib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000259	0.00288	CbGeAlD
Dasatinib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000257	0.00287	CbGeAlD
Dasatinib—KIT—kidney—type 2 diabetes mellitus	0.000253	0.00282	CbGeAlD
Dasatinib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000253	0.00282	CbGeAlD
Dasatinib—KIT—pancreas—type 2 diabetes mellitus	0.000251	0.0028	CbGeAlD
Dasatinib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000251	0.0028	CbGeAlD
Dasatinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000251	0.0028	CbGeAlD
Dasatinib—PDGFRB—kidney—type 2 diabetes mellitus	0.000247	0.00276	CbGeAlD
Dasatinib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000246	0.00275	CbGeAlD
Dasatinib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000245	0.00274	CbGeAlD
Dasatinib—MAPK14—liver—type 2 diabetes mellitus	0.000243	0.00272	CbGeAlD
Dasatinib—FGR—liver—type 2 diabetes mellitus	0.000242	0.0027	CbGeAlD
Dasatinib—LCK—liver—type 2 diabetes mellitus	0.000242	0.0027	CbGeAlD
Dasatinib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000241	0.00268	CbGeAlD
Dasatinib—FMO3—liver—type 2 diabetes mellitus	0.000234	0.00261	CbGeAlD
Dasatinib—EPHB4—liver—type 2 diabetes mellitus	0.000231	0.00257	CbGeAlD
Dasatinib—JAK2—liver—type 2 diabetes mellitus	0.000229	0.00256	CbGeAlD
Dasatinib—KIT—adipose tissue—type 2 diabetes mellitus	0.000228	0.00254	CbGeAlD
Dasatinib—EPHA2—liver—type 2 diabetes mellitus	0.000226	0.00252	CbGeAlD
Dasatinib—FYN—liver—type 2 diabetes mellitus	0.000226	0.00252	CbGeAlD
Dasatinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000225	0.00251	CbGeAlD
Dasatinib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000223	0.00248	CbGeAlD
Dasatinib—MAP4K5—liver—type 2 diabetes mellitus	0.000221	0.00246	CbGeAlD
Dasatinib—MAP3K3—liver—type 2 diabetes mellitus	0.000221	0.00246	CbGeAlD
Dasatinib—ABL1—kidney—type 2 diabetes mellitus	0.00022	0.00246	CbGeAlD
Dasatinib—ABL1—pancreas—type 2 diabetes mellitus	0.000219	0.00244	CbGeAlD
Dasatinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000214	0.00239	CbGeAlD
Dasatinib—CYP1B1—nephron tubule—type 2 diabetes mellitus	0.000212	0.00237	CbGeAlD
Dasatinib—YES1—liver—type 2 diabetes mellitus	0.000204	0.00227	CbGeAlD
Dasatinib—PDGFRA—liver—type 2 diabetes mellitus	0.0002	0.00223	CbGeAlD
Dasatinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000198	0.00221	CbGeAlD
Dasatinib—SRC—liver—type 2 diabetes mellitus	0.000196	0.00219	CbGeAlD
Dasatinib—CYP1B1—cardiovascular system—type 2 diabetes mellitus	0.000191	0.00213	CbGeAlD
Dasatinib—CYP1B1—kidney—type 2 diabetes mellitus	0.000187	0.00208	CbGeAlD
Dasatinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000182	0.00203	CbGeAlD
Dasatinib—CYP1B1—cortex of kidney—type 2 diabetes mellitus	0.000182	0.00203	CbGeAlD
Dasatinib—MAP2K5—liver—type 2 diabetes mellitus	0.00018	0.00201	CbGeAlD
Dasatinib—CSF1R—liver—type 2 diabetes mellitus	0.000176	0.00196	CbGeAlD
Dasatinib—CYP1B1—adipose tissue—type 2 diabetes mellitus	0.000168	0.00188	CbGeAlD
Dasatinib—KIT—liver—type 2 diabetes mellitus	0.00016	0.00178	CbGeAlD
Dasatinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000158	0.00176	CbGeAlD
Dasatinib—PDGFRB—liver—type 2 diabetes mellitus	0.000156	0.00174	CbGeAlD
Dasatinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000147	0.00164	CbGeAlD
Dasatinib—ABL1—liver—type 2 diabetes mellitus	0.000139	0.00155	CbGeAlD
Dasatinib—CYP1A1—kidney—type 2 diabetes mellitus	0.000132	0.00147	CbGeAlD
Dasatinib—CYP3A5—kidney—type 2 diabetes mellitus	0.000129	0.00144	CbGeAlD
Dasatinib—CYP3A5—pancreas—type 2 diabetes mellitus	0.000128	0.00143	CbGeAlD
Dasatinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000126	0.0014	CbGeAlD
Dasatinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000125	0.0014	CbGeAlD
Dasatinib—CYP1A1—adipose tissue—type 2 diabetes mellitus	0.000119	0.00133	CbGeAlD
Dasatinib—CYP1B1—liver—type 2 diabetes mellitus	0.000118	0.00132	CbGeAlD
Dasatinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000116	0.0013	CbGeAlD
Dasatinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	9.68e-05	0.00108	CbGeAlD
Dasatinib—CYP3A4—kidney—type 2 diabetes mellitus	9.67e-05	0.00108	CbGeAlD
Dasatinib—ABCG2—liver—type 2 diabetes mellitus	8.78e-05	0.000979	CbGeAlD
Dasatinib—CYP1A2—liver—type 2 diabetes mellitus	8.45e-05	0.000943	CbGeAlD
Dasatinib—CYP1A1—liver—type 2 diabetes mellitus	8.33e-05	0.00093	CbGeAlD
Dasatinib—ABCB1—retina—type 2 diabetes mellitus	8.27e-05	0.000923	CbGeAlD
Dasatinib—CYP3A5—liver—type 2 diabetes mellitus	8.15e-05	0.000909	CbGeAlD
Dasatinib—ABCB1—nephron tubule—type 2 diabetes mellitus	7.79e-05	0.000869	CbGeAlD
Dasatinib—Hypertension—Irbesartan—type 2 diabetes mellitus	7.55e-05	0.00043	CcSEcCtD
Dasatinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7.53e-05	0.000429	CcSEcCtD
Dasatinib—Flushing—Ramipril—type 2 diabetes mellitus	7.52e-05	0.000428	CcSEcCtD
Dasatinib—Infection—Metformin—type 2 diabetes mellitus	7.51e-05	0.000428	CcSEcCtD
Dasatinib—Insomnia—Valsartan—type 2 diabetes mellitus	7.51e-05	0.000427	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.48e-05	0.000425	CcSEcCtD
Dasatinib—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	7.45e-05	0.000424	CcSEcCtD
Dasatinib—Chest pain—Irbesartan—type 2 diabetes mellitus	7.44e-05	0.000424	CcSEcCtD
Dasatinib—Arthralgia—Irbesartan—type 2 diabetes mellitus	7.44e-05	0.000424	CcSEcCtD
Dasatinib—Myalgia—Irbesartan—type 2 diabetes mellitus	7.44e-05	0.000424	CcSEcCtD
Dasatinib—Shock—Metformin—type 2 diabetes mellitus	7.44e-05	0.000423	CcSEcCtD
Dasatinib—Insomnia—Orlistat—type 2 diabetes mellitus	7.42e-05	0.000422	CcSEcCtD
Dasatinib—Malaise—Losartan—type 2 diabetes mellitus	7.42e-05	0.000422	CcSEcCtD
Dasatinib—Anxiety—Irbesartan—type 2 diabetes mellitus	7.42e-05	0.000422	CcSEcCtD
Dasatinib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	7.42e-05	0.000422	CcSEcCtD
Dasatinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	7.42e-05	0.000422	CcSEcCtD
Dasatinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	7.4e-05	0.000421	CcSEcCtD
Dasatinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000421	CcSEcCtD
Dasatinib—Vertigo—Losartan—type 2 diabetes mellitus	7.39e-05	0.000421	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	7.39e-05	0.000421	CcSEcCtD
Dasatinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	7.39e-05	0.000421	CcSEcCtD
Dasatinib—Somnolence—Valsartan—type 2 diabetes mellitus	7.38e-05	0.00042	CcSEcCtD
Dasatinib—Syncope—Losartan—type 2 diabetes mellitus	7.38e-05	0.00042	CcSEcCtD
Dasatinib—Discomfort—Irbesartan—type 2 diabetes mellitus	7.36e-05	0.000419	CcSEcCtD
Dasatinib—Skin disorder—Metformin—type 2 diabetes mellitus	7.35e-05	0.000418	CcSEcCtD
Dasatinib—Immune system disorder—Ramipril—type 2 diabetes mellitus	7.32e-05	0.000417	CcSEcCtD
Dasatinib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	7.31e-05	0.000416	CcSEcCtD
Dasatinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	7.31e-05	0.000416	CcSEcCtD
Dasatinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	7.31e-05	0.000416	CcSEcCtD
Dasatinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.28e-05	0.000414	CcSEcCtD
Dasatinib—Palpitations—Losartan—type 2 diabetes mellitus	7.27e-05	0.000414	CcSEcCtD
Dasatinib—Nausea—Glimepiride—type 2 diabetes mellitus	7.25e-05	0.000413	CcSEcCtD
Dasatinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	7.24e-05	0.000412	CcSEcCtD
Dasatinib—Loss of consciousness—Losartan—type 2 diabetes mellitus	7.23e-05	0.000412	CcSEcCtD
Dasatinib—Nausea—Sitagliptin—type 2 diabetes mellitus	7.23e-05	0.000411	CcSEcCtD
Dasatinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.22e-05	0.000411	CcSEcCtD
Dasatinib—Asthenia—Glyburide—type 2 diabetes mellitus	7.22e-05	0.000411	CcSEcCtD
Dasatinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.22e-05	0.000411	CcSEcCtD
Dasatinib—Anorexia—Metformin—type 2 diabetes mellitus	7.21e-05	0.00041	CcSEcCtD
Dasatinib—Cough—Losartan—type 2 diabetes mellitus	7.18e-05	0.000409	CcSEcCtD
Dasatinib—Urticaria—Gliclazide—type 2 diabetes mellitus	7.18e-05	0.000409	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.17e-05	0.000408	CcSEcCtD
Dasatinib—Alopecia—Ramipril—type 2 diabetes mellitus	7.16e-05	0.000408	CcSEcCtD
Dasatinib—Fatigue—Valsartan—type 2 diabetes mellitus	7.16e-05	0.000407	CcSEcCtD
Dasatinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.15e-05	0.000407	CcSEcCtD
Dasatinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	7.15e-05	0.000407	CcSEcCtD
Dasatinib—Oedema—Irbesartan—type 2 diabetes mellitus	7.14e-05	0.000406	CcSEcCtD
Dasatinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.13e-05	0.000406	CcSEcCtD
Dasatinib—Pruritus—Glyburide—type 2 diabetes mellitus	7.12e-05	0.000405	CcSEcCtD
Dasatinib—Mental disorder—Ramipril—type 2 diabetes mellitus	7.1e-05	0.000404	CcSEcCtD
Dasatinib—Constipation—Valsartan—type 2 diabetes mellitus	7.1e-05	0.000404	CcSEcCtD
Dasatinib—Infection—Irbesartan—type 2 diabetes mellitus	7.09e-05	0.000403	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.08e-05	0.000403	CcSEcCtD
Dasatinib—Fatigue—Orlistat—type 2 diabetes mellitus	7.07e-05	0.000403	CcSEcCtD
Dasatinib—Hypotension—Metformin—type 2 diabetes mellitus	7.07e-05	0.000402	CcSEcCtD
Dasatinib—Erythema—Ramipril—type 2 diabetes mellitus	7.06e-05	0.000402	CcSEcCtD
Dasatinib—Malnutrition—Ramipril—type 2 diabetes mellitus	7.06e-05	0.000402	CcSEcCtD
Dasatinib—Shock—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.0004	CcSEcCtD
Dasatinib—Pain—Orlistat—type 2 diabetes mellitus	7.02e-05	0.000399	CcSEcCtD
Dasatinib—Chest pain—Losartan—type 2 diabetes mellitus	7.01e-05	0.000399	CcSEcCtD
Dasatinib—Myalgia—Losartan—type 2 diabetes mellitus	7.01e-05	0.000399	CcSEcCtD
Dasatinib—Arthralgia—Losartan—type 2 diabetes mellitus	7.01e-05	0.000399	CcSEcCtD
Dasatinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	7e-05	0.000398	CcSEcCtD
Dasatinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	7e-05	0.000781	CbGeAlD
Dasatinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	7e-05	0.000398	CcSEcCtD
Dasatinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.99e-05	0.000398	CcSEcCtD
Dasatinib—Anxiety—Losartan—type 2 diabetes mellitus	6.98e-05	0.000397	CcSEcCtD
Dasatinib—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.97e-05	0.000396	CcSEcCtD
Dasatinib—Rash—Bromocriptine—type 2 diabetes mellitus	6.94e-05	0.000395	CcSEcCtD
Dasatinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.94e-05	0.000395	CcSEcCtD
Dasatinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.93e-05	0.000394	CcSEcCtD
Dasatinib—Discomfort—Losartan—type 2 diabetes mellitus	6.92e-05	0.000394	CcSEcCtD
Dasatinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.91e-05	0.000393	CcSEcCtD
Dasatinib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000393	CcSEcCtD
Dasatinib—Headache—Bromocriptine—type 2 diabetes mellitus	6.9e-05	0.000393	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.89e-05	0.000392	CcSEcCtD
Dasatinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.89e-05	0.000392	CcSEcCtD
Dasatinib—ABCB1—kidney—type 2 diabetes mellitus	6.85e-05	0.000764	CbGeAlD
Dasatinib—ABCB1—pancreas—type 2 diabetes mellitus	6.8e-05	0.000759	CbGeAlD
Dasatinib—Anorexia—Irbesartan—type 2 diabetes mellitus	6.8e-05	0.000387	CcSEcCtD
Dasatinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.79e-05	0.000386	CcSEcCtD
Dasatinib—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.78e-05	0.000386	CcSEcCtD
Dasatinib—Confusional state—Losartan—type 2 diabetes mellitus	6.77e-05	0.000385	CcSEcCtD
Dasatinib—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.76e-05	0.000385	CcSEcCtD
Dasatinib—Dyspnoea—Metformin—type 2 diabetes mellitus	6.74e-05	0.000384	CcSEcCtD
Dasatinib—Somnolence—Metformin—type 2 diabetes mellitus	6.72e-05	0.000383	CcSEcCtD
Dasatinib—Oedema—Losartan—type 2 diabetes mellitus	6.72e-05	0.000382	CcSEcCtD
Dasatinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.71e-05	0.000382	CcSEcCtD
Dasatinib—Infection—Losartan—type 2 diabetes mellitus	6.67e-05	0.00038	CcSEcCtD
Dasatinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	6.67e-05	0.000744	CbGeAlD
Dasatinib—Hypotension—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.00038	CcSEcCtD
Dasatinib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.66e-05	0.000379	CcSEcCtD
Dasatinib—Dyspepsia—Metformin—type 2 diabetes mellitus	6.66e-05	0.000379	CcSEcCtD
Dasatinib—Tremor—Ramipril—type 2 diabetes mellitus	6.61e-05	0.000376	CcSEcCtD
Dasatinib—Shock—Losartan—type 2 diabetes mellitus	6.61e-05	0.000376	CcSEcCtD
Dasatinib—Urticaria—Valsartan—type 2 diabetes mellitus	6.6e-05	0.000375	CcSEcCtD
Dasatinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.59e-05	0.000375	CcSEcCtD
Dasatinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.58e-05	0.000374	CcSEcCtD
Dasatinib—Decreased appetite—Metformin—type 2 diabetes mellitus	6.57e-05	0.000374	CcSEcCtD
Dasatinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.56e-05	0.000374	CcSEcCtD
Dasatinib—Tachycardia—Losartan—type 2 diabetes mellitus	6.55e-05	0.000373	CcSEcCtD
Dasatinib—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	6.55e-05	0.000373	CcSEcCtD
Dasatinib—Nausea—Bromocriptine—type 2 diabetes mellitus	6.54e-05	0.000372	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.53e-05	0.000372	CcSEcCtD
Dasatinib—Fatigue—Metformin—type 2 diabetes mellitus	6.52e-05	0.000371	CcSEcCtD
Dasatinib—Urticaria—Orlistat—type 2 diabetes mellitus	6.52e-05	0.000371	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.00037	CcSEcCtD
Dasatinib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.49e-05	0.00037	CcSEcCtD
Dasatinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.49e-05	0.000369	CcSEcCtD
Dasatinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.49e-05	0.000369	CcSEcCtD
Dasatinib—Asthenia—Gliclazide—type 2 diabetes mellitus	6.48e-05	0.000369	CcSEcCtD
Dasatinib—Constipation—Metformin—type 2 diabetes mellitus	6.47e-05	0.000368	CcSEcCtD
Dasatinib—Anorexia—Losartan—type 2 diabetes mellitus	6.4e-05	0.000364	CcSEcCtD
Dasatinib—Vomiting—Glyburide—type 2 diabetes mellitus	6.4e-05	0.000364	CcSEcCtD
Dasatinib—Pruritus—Gliclazide—type 2 diabetes mellitus	6.39e-05	0.000364	CcSEcCtD
Dasatinib—Malaise—Ramipril—type 2 diabetes mellitus	6.36e-05	0.000362	CcSEcCtD
Dasatinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.000362	CcSEcCtD
Dasatinib—Rash—Glyburide—type 2 diabetes mellitus	6.35e-05	0.000361	CcSEcCtD
Dasatinib—Somnolence—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000361	CcSEcCtD
Dasatinib—Dermatitis—Glyburide—type 2 diabetes mellitus	6.34e-05	0.000361	CcSEcCtD
Dasatinib—Vertigo—Ramipril—type 2 diabetes mellitus	6.34e-05	0.000361	CcSEcCtD
Dasatinib—Syncope—Ramipril—type 2 diabetes mellitus	6.33e-05	0.00036	CcSEcCtD
Dasatinib—Headache—Glyburide—type 2 diabetes mellitus	6.31e-05	0.000359	CcSEcCtD
Dasatinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.28e-05	0.000358	CcSEcCtD
Dasatinib—Hypotension—Losartan—type 2 diabetes mellitus	6.28e-05	0.000357	CcSEcCtD
Dasatinib—Palpitations—Ramipril—type 2 diabetes mellitus	6.24e-05	0.000355	CcSEcCtD
Dasatinib—Feeling abnormal—Metformin—type 2 diabetes mellitus	6.23e-05	0.000355	CcSEcCtD
Dasatinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.2e-05	0.000353	CcSEcCtD
Dasatinib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	6.2e-05	0.000353	CcSEcCtD
Dasatinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.18e-05	0.000352	CcSEcCtD
Dasatinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.18e-05	0.000352	CcSEcCtD
Dasatinib—ABCB1—adipose tissue—type 2 diabetes mellitus	6.17e-05	0.000689	CbGeAlD
Dasatinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.16e-05	0.000351	CcSEcCtD
Dasatinib—Cough—Ramipril—type 2 diabetes mellitus	6.16e-05	0.00035	CcSEcCtD
Dasatinib—Fatigue—Irbesartan—type 2 diabetes mellitus	6.15e-05	0.00035	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.12e-05	0.000348	CcSEcCtD
Dasatinib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	6.12e-05	0.000348	CcSEcCtD
Dasatinib—CYP3A4—liver—type 2 diabetes mellitus	6.11e-05	0.000682	CbGeAlD
Dasatinib—Convulsion—Ramipril—type 2 diabetes mellitus	6.11e-05	0.000348	CcSEcCtD
Dasatinib—Pain—Irbesartan—type 2 diabetes mellitus	6.1e-05	0.000347	CcSEcCtD
Dasatinib—Constipation—Irbesartan—type 2 diabetes mellitus	6.1e-05	0.000347	CcSEcCtD
Dasatinib—Insomnia—Losartan—type 2 diabetes mellitus	6.07e-05	0.000346	CcSEcCtD
Dasatinib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	6.05e-05	0.000344	CcSEcCtD
Dasatinib—Urticaria—Metformin—type 2 diabetes mellitus	6.01e-05	0.000342	CcSEcCtD
Dasatinib—Arthralgia—Ramipril—type 2 diabetes mellitus	6.01e-05	0.000342	CcSEcCtD
Dasatinib—Chest pain—Ramipril—type 2 diabetes mellitus	6.01e-05	0.000342	CcSEcCtD
Dasatinib—Myalgia—Ramipril—type 2 diabetes mellitus	6.01e-05	0.000342	CcSEcCtD
Dasatinib—Dyspnoea—Losartan—type 2 diabetes mellitus	5.99e-05	0.000341	CcSEcCtD
Dasatinib—Anxiety—Ramipril—type 2 diabetes mellitus	5.99e-05	0.000341	CcSEcCtD
Dasatinib—Nausea—Glyburide—type 2 diabetes mellitus	5.98e-05	0.00034	CcSEcCtD
Dasatinib—Abdominal pain—Metformin—type 2 diabetes mellitus	5.98e-05	0.00034	CcSEcCtD
Dasatinib—Dizziness—Gliclazide—type 2 diabetes mellitus	5.98e-05	0.00034	CcSEcCtD
Dasatinib—Somnolence—Losartan—type 2 diabetes mellitus	5.97e-05	0.00034	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.97e-05	0.00034	CcSEcCtD
Dasatinib—Asthenia—Valsartan—type 2 diabetes mellitus	5.96e-05	0.000339	CcSEcCtD
Dasatinib—Discomfort—Ramipril—type 2 diabetes mellitus	5.94e-05	0.000338	CcSEcCtD
Dasatinib—Dyspepsia—Losartan—type 2 diabetes mellitus	5.91e-05	0.000336	CcSEcCtD
Dasatinib—Asthenia—Orlistat—type 2 diabetes mellitus	5.89e-05	0.000335	CcSEcCtD
Dasatinib—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.88e-05	0.000335	CcSEcCtD
Dasatinib—Pruritus—Valsartan—type 2 diabetes mellitus	5.88e-05	0.000334	CcSEcCtD
Dasatinib—Decreased appetite—Losartan—type 2 diabetes mellitus	5.84e-05	0.000332	CcSEcCtD
Dasatinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000332	CcSEcCtD
Dasatinib—Confusional state—Ramipril—type 2 diabetes mellitus	5.81e-05	0.00033	CcSEcCtD
Dasatinib—Pruritus—Orlistat—type 2 diabetes mellitus	5.81e-05	0.00033	CcSEcCtD
Dasatinib—Fatigue—Losartan—type 2 diabetes mellitus	5.79e-05	0.00033	CcSEcCtD
Dasatinib—Oedema—Ramipril—type 2 diabetes mellitus	5.76e-05	0.000328	CcSEcCtD
Dasatinib—Vomiting—Gliclazide—type 2 diabetes mellitus	5.75e-05	0.000327	CcSEcCtD
Dasatinib—Pain—Losartan—type 2 diabetes mellitus	5.74e-05	0.000327	CcSEcCtD
Dasatinib—Constipation—Losartan—type 2 diabetes mellitus	5.74e-05	0.000327	CcSEcCtD
Dasatinib—Rash—Gliclazide—type 2 diabetes mellitus	5.7e-05	0.000324	CcSEcCtD
Dasatinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.69e-05	0.000324	CcSEcCtD
Dasatinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.68e-05	0.000323	CcSEcCtD
Dasatinib—Urticaria—Irbesartan—type 2 diabetes mellitus	5.67e-05	0.000323	CcSEcCtD
Dasatinib—Shock—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000322	CcSEcCtD
Dasatinib—Headache—Gliclazide—type 2 diabetes mellitus	5.66e-05	0.000322	CcSEcCtD
Dasatinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.65e-05	0.000321	CcSEcCtD
Dasatinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.64e-05	0.000321	CcSEcCtD
Dasatinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.64e-05	0.000321	CcSEcCtD
Dasatinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.64e-05	0.000321	CcSEcCtD
Dasatinib—Tachycardia—Ramipril—type 2 diabetes mellitus	5.62e-05	0.00032	CcSEcCtD
Dasatinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.61e-05	0.00032	CcSEcCtD
Dasatinib—Skin disorder—Ramipril—type 2 diabetes mellitus	5.59e-05	0.000318	CcSEcCtD
Dasatinib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000317	CcSEcCtD
Dasatinib—Feeling abnormal—Losartan—type 2 diabetes mellitus	5.53e-05	0.000315	CcSEcCtD
Dasatinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.49e-05	0.000313	CcSEcCtD
Dasatinib—Dizziness—Valsartan—type 2 diabetes mellitus	5.49e-05	0.000313	CcSEcCtD
Dasatinib—Anorexia—Ramipril—type 2 diabetes mellitus	5.49e-05	0.000312	CcSEcCtD
Dasatinib—Dizziness—Orlistat—type 2 diabetes mellitus	5.43e-05	0.000309	CcSEcCtD
Dasatinib—Asthenia—Metformin—type 2 diabetes mellitus	5.43e-05	0.000309	CcSEcCtD
Dasatinib—Hypotension—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000306	CcSEcCtD
Dasatinib—Nausea—Gliclazide—type 2 diabetes mellitus	5.37e-05	0.000306	CcSEcCtD
Dasatinib—Pruritus—Metformin—type 2 diabetes mellitus	5.35e-05	0.000304	CcSEcCtD
Dasatinib—Urticaria—Losartan—type 2 diabetes mellitus	5.34e-05	0.000304	CcSEcCtD
Dasatinib—Abdominal pain—Losartan—type 2 diabetes mellitus	5.31e-05	0.000302	CcSEcCtD
Dasatinib—Body temperature increased—Losartan—type 2 diabetes mellitus	5.31e-05	0.000302	CcSEcCtD
Dasatinib—Vomiting—Valsartan—type 2 diabetes mellitus	5.28e-05	0.0003	CcSEcCtD
Dasatinib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.26e-05	0.000299	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000299	CcSEcCtD
Dasatinib—Rash—Valsartan—type 2 diabetes mellitus	5.24e-05	0.000298	CcSEcCtD
Dasatinib—Dermatitis—Valsartan—type 2 diabetes mellitus	5.23e-05	0.000298	CcSEcCtD
Dasatinib—Vomiting—Orlistat—type 2 diabetes mellitus	5.22e-05	0.000297	CcSEcCtD
Dasatinib—Insomnia—Ramipril—type 2 diabetes mellitus	5.21e-05	0.000296	CcSEcCtD
Dasatinib—Headache—Valsartan—type 2 diabetes mellitus	5.2e-05	0.000296	CcSEcCtD
Dasatinib—Diarrhoea—Metformin—type 2 diabetes mellitus	5.17e-05	0.000294	CcSEcCtD
Dasatinib—Rash—Orlistat—type 2 diabetes mellitus	5.17e-05	0.000294	CcSEcCtD
Dasatinib—Dermatitis—Orlistat—type 2 diabetes mellitus	5.17e-05	0.000294	CcSEcCtD
Dasatinib—Headache—Orlistat—type 2 diabetes mellitus	5.14e-05	0.000293	CcSEcCtD
Dasatinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000292	CcSEcCtD
Dasatinib—Asthenia—Irbesartan—type 2 diabetes mellitus	5.12e-05	0.000291	CcSEcCtD
Dasatinib—Somnolence—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000291	CcSEcCtD
Dasatinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000288	CcSEcCtD
Dasatinib—Pruritus—Irbesartan—type 2 diabetes mellitus	5.05e-05	0.000287	CcSEcCtD
Dasatinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	5.01e-05	0.000285	CcSEcCtD
Dasatinib—Dizziness—Metformin—type 2 diabetes mellitus	5e-05	0.000285	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.97e-05	0.000283	CcSEcCtD
Dasatinib—Fatigue—Ramipril—type 2 diabetes mellitus	4.97e-05	0.000283	CcSEcCtD
Dasatinib—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.95e-05	0.000282	CcSEcCtD
Dasatinib—Nausea—Valsartan—type 2 diabetes mellitus	4.93e-05	0.000281	CcSEcCtD
Dasatinib—Constipation—Ramipril—type 2 diabetes mellitus	4.92e-05	0.00028	CcSEcCtD
Dasatinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.88e-05	0.000278	CcSEcCtD
Dasatinib—Nausea—Orlistat—type 2 diabetes mellitus	4.87e-05	0.000277	CcSEcCtD
Dasatinib—Asthenia—Losartan—type 2 diabetes mellitus	4.82e-05	0.000274	CcSEcCtD
Dasatinib—Vomiting—Metformin—type 2 diabetes mellitus	4.81e-05	0.000274	CcSEcCtD
Dasatinib—Rash—Metformin—type 2 diabetes mellitus	4.77e-05	0.000271	CcSEcCtD
Dasatinib—Dermatitis—Metformin—type 2 diabetes mellitus	4.76e-05	0.000271	CcSEcCtD
Dasatinib—Pruritus—Losartan—type 2 diabetes mellitus	4.75e-05	0.00027	CcSEcCtD
Dasatinib—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.75e-05	0.00027	CcSEcCtD
Dasatinib—Headache—Metformin—type 2 diabetes mellitus	4.74e-05	0.00027	CcSEcCtD
Dasatinib—Dizziness—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.000269	CcSEcCtD
Dasatinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.71e-05	0.000268	CcSEcCtD
Dasatinib—Diarrhoea—Losartan—type 2 diabetes mellitus	4.6e-05	0.000262	CcSEcCtD
Dasatinib—Urticaria—Ramipril—type 2 diabetes mellitus	4.57e-05	0.00026	CcSEcCtD
Dasatinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000259	CcSEcCtD
Dasatinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000259	CcSEcCtD
Dasatinib—Vomiting—Irbesartan—type 2 diabetes mellitus	4.54e-05	0.000258	CcSEcCtD
Dasatinib—Rash—Irbesartan—type 2 diabetes mellitus	4.5e-05	0.000256	CcSEcCtD
Dasatinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.5e-05	0.000256	CcSEcCtD
Dasatinib—Nausea—Metformin—type 2 diabetes mellitus	4.49e-05	0.000256	CcSEcCtD
Dasatinib—Headache—Irbesartan—type 2 diabetes mellitus	4.47e-05	0.000254	CcSEcCtD
Dasatinib—Dizziness—Losartan—type 2 diabetes mellitus	4.44e-05	0.000253	CcSEcCtD
Dasatinib—ABCB1—liver—type 2 diabetes mellitus	4.33e-05	0.000483	CbGeAlD
Dasatinib—Vomiting—Losartan—type 2 diabetes mellitus	4.27e-05	0.000243	CcSEcCtD
Dasatinib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.24e-05	0.000241	CcSEcCtD
Dasatinib—Nausea—Irbesartan—type 2 diabetes mellitus	4.24e-05	0.000241	CcSEcCtD
Dasatinib—Rash—Losartan—type 2 diabetes mellitus	4.23e-05	0.000241	CcSEcCtD
Dasatinib—Dermatitis—Losartan—type 2 diabetes mellitus	4.23e-05	0.000241	CcSEcCtD
Dasatinib—Headache—Losartan—type 2 diabetes mellitus	4.21e-05	0.000239	CcSEcCtD
Dasatinib—Asthenia—Ramipril—type 2 diabetes mellitus	4.13e-05	0.000235	CcSEcCtD
Dasatinib—Pruritus—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000232	CcSEcCtD
Dasatinib—Nausea—Losartan—type 2 diabetes mellitus	3.99e-05	0.000227	CcSEcCtD
Dasatinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.94e-05	0.000224	CcSEcCtD
Dasatinib—Dizziness—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000217	CcSEcCtD
Dasatinib—Vomiting—Ramipril—type 2 diabetes mellitus	3.66e-05	0.000208	CcSEcCtD
Dasatinib—Rash—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000207	CcSEcCtD
Dasatinib—Dermatitis—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000206	CcSEcCtD
Dasatinib—Headache—Ramipril—type 2 diabetes mellitus	3.61e-05	0.000205	CcSEcCtD
Dasatinib—Nausea—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000195	CcSEcCtD
Dasatinib—JAK2—Disease—EGFR—type 2 diabetes mellitus	8.29e-07	4.55e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—SRC—type 2 diabetes mellitus	8.28e-07	4.55e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	8.27e-07	4.54e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.26e-07	4.54e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—type 2 diabetes mellitus	8.26e-07	4.54e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.25e-07	4.54e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	8.23e-07	4.53e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.21e-07	4.51e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	8.21e-07	4.51e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	8.19e-07	4.5e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—type 2 diabetes mellitus	8.15e-07	4.48e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—type 2 diabetes mellitus	8.14e-07	4.48e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—type 2 diabetes mellitus	8.13e-07	4.47e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.12e-07	4.46e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	8.11e-07	4.46e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	8.1e-07	4.45e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	8.1e-07	4.45e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	8.09e-07	4.45e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	8.05e-07	4.42e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	8.02e-07	4.41e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.99e-07	4.39e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	7.97e-07	4.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	7.95e-07	4.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	7.95e-07	4.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	7.94e-07	4.37e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—INS—type 2 diabetes mellitus	7.91e-07	4.35e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	7.89e-07	4.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	7.89e-07	4.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	7.89e-07	4.34e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	7.86e-07	4.32e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	7.84e-07	4.31e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.84e-07	4.31e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.84e-07	4.31e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.84e-07	4.31e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	7.82e-07	4.3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.81e-07	4.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.79e-07	4.28e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.75e-07	4.26e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	7.71e-07	4.24e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	7.71e-07	4.24e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	7.7e-07	4.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.7e-07	4.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.67e-07	4.22e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.67e-07	4.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	7.65e-07	4.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.65e-07	4.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.65e-07	4.2e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	7.63e-07	4.19e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.62e-07	4.19e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	7.62e-07	4.19e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.6e-07	4.18e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.59e-07	4.17e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.57e-07	4.16e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	7.56e-07	4.16e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.55e-07	4.15e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	7.55e-07	4.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.55e-07	4.15e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	7.53e-07	4.14e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—type 2 diabetes mellitus	7.52e-07	4.13e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.47e-07	4.11e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	7.43e-07	4.08e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.43e-07	4.08e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	7.42e-07	4.08e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	7.4e-07	4.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	7.38e-07	4.06e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—type 2 diabetes mellitus	7.37e-07	4.05e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	7.34e-07	4.03e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	7.34e-07	4.03e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—type 2 diabetes mellitus	7.28e-07	4e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.27e-07	4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.27e-07	4e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—type 2 diabetes mellitus	7.26e-07	3.99e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—type 2 diabetes mellitus	7.26e-07	3.99e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	7.22e-07	3.97e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.2e-07	3.96e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.18e-07	3.95e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.17e-07	3.94e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	7.15e-07	3.93e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	7.12e-07	3.91e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.1e-07	3.9e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.08e-07	3.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.08e-07	3.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.08e-07	3.89e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	7.07e-07	3.89e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	7.04e-07	3.87e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.04e-07	3.87e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.03e-07	3.86e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	7.01e-07	3.85e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—type 2 diabetes mellitus	6.99e-07	3.84e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.97e-07	3.83e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—type 2 diabetes mellitus	6.96e-07	3.83e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.96e-07	3.83e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—type 2 diabetes mellitus	6.96e-07	3.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	6.95e-07	3.82e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	6.95e-07	3.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	6.94e-07	3.82e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.94e-07	3.81e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.94e-07	3.81e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	6.91e-07	3.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—type 2 diabetes mellitus	6.9e-07	3.79e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.89e-07	3.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	6.89e-07	3.79e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	6.86e-07	3.77e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.86e-07	3.77e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	6.82e-07	3.75e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	6.8e-07	3.74e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—type 2 diabetes mellitus	6.8e-07	3.74e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.78e-07	3.73e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	6.77e-07	3.72e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	6.74e-07	3.7e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	6.73e-07	3.7e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.72e-07	3.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—type 2 diabetes mellitus	6.71e-07	3.69e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—type 2 diabetes mellitus	6.7e-07	3.68e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—type 2 diabetes mellitus	6.69e-07	3.68e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	6.69e-07	3.68e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.65e-07	3.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—type 2 diabetes mellitus	6.62e-07	3.64e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	6.58e-07	3.62e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	6.55e-07	3.6e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—type 2 diabetes mellitus	6.55e-07	3.6e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	6.54e-07	3.59e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RELA—type 2 diabetes mellitus	6.53e-07	3.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.53e-07	3.59e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	6.51e-07	3.58e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	6.51e-07	3.58e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	6.48e-07	3.56e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.48e-07	3.56e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.46e-07	3.55e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.45e-07	3.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—type 2 diabetes mellitus	6.45e-07	3.54e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	6.43e-07	3.53e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—type 2 diabetes mellitus	6.42e-07	3.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	6.41e-07	3.52e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—type 2 diabetes mellitus	6.41e-07	3.52e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	6.4e-07	3.52e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	6.4e-07	3.52e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.39e-07	3.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—type 2 diabetes mellitus	6.37e-07	3.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—type 2 diabetes mellitus	6.36e-07	3.5e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	6.36e-07	3.5e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.33e-07	3.48e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.32e-07	3.48e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.29e-07	3.46e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	6.24e-07	3.43e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.23e-07	3.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.22e-07	3.42e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.2e-07	3.41e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—type 2 diabetes mellitus	6.18e-07	3.4e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	6.15e-07	3.38e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	6.15e-07	3.38e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.14e-07	3.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.14e-07	3.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	6.11e-07	3.36e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.1e-07	3.36e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	6.09e-07	3.35e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—type 2 diabetes mellitus	6.04e-07	3.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.99e-07	3.3e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	5.95e-07	3.27e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	5.93e-07	3.26e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.92e-07	3.25e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.9e-07	3.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.89e-07	3.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.88e-07	3.23e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—type 2 diabetes mellitus	5.87e-07	3.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	5.86e-07	3.22e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.8e-07	3.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	5.8e-07	3.19e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	5.71e-07	3.14e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	5.71e-07	3.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.65e-07	3.1e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	5.62e-07	3.09e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	5.62e-07	3.09e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	5.6e-07	3.08e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—type 2 diabetes mellitus	5.58e-07	3.07e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	5.57e-07	3.06e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.57e-07	3.06e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	5.51e-07	3.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.51e-07	3.03e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	5.4e-07	2.97e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—type 2 diabetes mellitus	5.35e-07	2.94e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	5.34e-07	2.94e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.29e-07	2.91e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.29e-07	2.91e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.27e-07	2.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.26e-07	2.89e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	5.25e-07	2.89e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	5.23e-07	2.88e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.2e-07	2.86e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.18e-07	2.85e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	5.17e-07	2.84e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—type 2 diabetes mellitus	5.15e-07	2.83e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	5.13e-07	2.82e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.08e-07	2.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.04e-07	2.77e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5e-07	2.75e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.98e-07	2.74e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—type 2 diabetes mellitus	4.94e-07	2.71e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—type 2 diabetes mellitus	4.93e-07	2.71e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	4.91e-07	2.7e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	4.91e-07	2.7e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.91e-07	2.7e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	4.87e-07	2.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.82e-07	2.65e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	4.76e-07	2.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4.72e-07	2.59e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.7e-07	2.58e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—type 2 diabetes mellitus	4.69e-07	2.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.59e-07	2.52e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—type 2 diabetes mellitus	4.59e-07	2.52e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.58e-07	2.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	4.56e-07	2.5e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—type 2 diabetes mellitus	4.55e-07	2.5e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.52e-07	2.48e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—type 2 diabetes mellitus	4.52e-07	2.48e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.5e-07	2.47e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	4.49e-07	2.47e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.49e-07	2.47e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	4.47e-07	2.46e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—type 2 diabetes mellitus	4.46e-07	2.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.4e-07	2.42e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.34e-07	2.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.33e-07	2.38e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.25e-07	2.34e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	4.17e-07	2.29e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.17e-07	2.29e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.12e-07	2.27e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.11e-07	2.26e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	4.1e-07	2.25e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.05e-07	2.23e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.04e-07	2.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.99e-07	2.19e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.92e-07	2.15e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	3.92e-07	2.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	3.91e-07	2.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.6e-07	1.98e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	3.58e-07	1.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.52e-07	1.93e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—type 2 diabetes mellitus	3.46e-07	1.9e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.45e-07	1.9e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.19e-07	1.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.16e-07	1.74e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.02e-07	1.66e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.02e-07	1.66e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	2.99e-07	1.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	2.83e-07	1.55e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.77e-07	1.52e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	2.26e-07	1.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.8e-07	9.9e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.39e-07	7.64e-07	CbGpPWpGaD
